BCR and lymphoma: We have demonstrated that pharmacological inhibition of these kinases impairs BCR-controlled integrin-mediated adhesion in vitro, in line with the clinically observed lymphocytosis in CLL, MCL, and WM patients, reflecting the mobilization of the malignant cells from their protective lymphoid organ microenvironment into the circulation, resulting in deprivation of critical growth- and survival-factors, followed by lymphoma regression2–7,9–13.